FDA nod for Sephience boosts PTC Therapeutics stock
PTC Therapeutics jumped after the FDA approved Sephience for PKU patients as young as one month. The label was supported by strong Phase 3 data showing sustained drops in phenylalanine. Analysts flagged it as a key catalyst; Citi raised its price target to $50. Retail sentiment turned 'extremely bullish' on Stocktwits.